Difference between revisions of "Dovitinib (TKI-258)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Chemotherapy" to "Category:Chemotherapeutic")
m (Text replacement - "http://www.cancer.gov" to "https://www.cancer.gov")
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
=Mechanism of action=
+
==Mechanism of action==
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=488976 NCI Drug Dictionary]: The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis.
+
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=488976 NCI Drug Dictionary]: The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis.
 +
 
 +
==Also known as==
 +
*'''Code names:''' CHIR-258, TKI-258
 +
*'''Generic name:''' dovitinib lactate
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
[[Category:Chemotherapeutic]]
+
 
 
[[Category:Oral medications]]
 
[[Category:Oral medications]]
  
[[Category:Kinase inhibitors]]
+
[[Category:CSF1R inhibitors]]
 
[[Category:FGFR inhibitors]]
 
[[Category:FGFR inhibitors]]
 +
[[Category:FLT3 inhibitors]]
 +
[[Category:KIT inhibitors]]
 +
[[Category:PDGFR inhibitors]]
 +
[[Category:VEGFR inhibitors]]
  
[[Category:Investigational]]
+
[[Category:Investigational drugs]]

Latest revision as of 20:19, 27 June 2024

Mechanism of action

From the NCI Drug Dictionary: The orally bioavailable lactate salt of a benzimidazole-quinolinone compound with potential antineoplastic activity. Dovitinib strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. In addition, this agent may inhibit other members of the RTK superfamily, including the vascular endothelial growth factor receptor; fibroblast growth factor receptor 1; platelet-derived growth factor receptor type 3; FMS-like tyrosine kinase 3; stem cell factor receptor (c-KIT); and colony-stimulating factor receptor 1; this may result in an additional reduction in cellular proliferation and angiogenesis, and the induction of tumor cell apoptosis.

Also known as

  • Code names: CHIR-258, TKI-258
  • Generic name: dovitinib lactate